Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-WARTS: Gardasil 9 for difficult-to-treat palmar and plantar warts
2024-513671-40-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in verruca, common wart and plantar wart (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jun 2022; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
verrucacommon wartplantar wart
Beyond the preview
Go deeper on 2024-513671-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513671-40-00.